Integrating NGS proteomics with genomics to improve immunotherapy outcomes in oncology
Date: Apr 23, 2025
We highlight how Olink® Explore 3072 supported biomarker discovery in the ASTRUM-005 trial of serplulimab in ES-SCLC. A 15-protein signature predicted treatment response, with additional genomic and hematological markers improving patient stratification and outcomes.
Application focusAdvancing Precision Medicine in Inflammatory Diseases with Affinity-Based Proteomics
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting joints, entheses, and skin, and is linked to higher risks of cardiovascular disease and MASLD. These associations reflect complex inflammation-metabolism interactions, but treatment effects remain unclear.
10 Apr 2025
- Application focus
Integrating plasma proteomics to identify tuberculosis-specific diagnostic biomarkers
Using mass spectrometry, Olink’s proximity extension assay, cross-disciplinary research, and international collaboration, Dr. Schiff and team have identified protein biomarkers with high TB-specificity and demonstrated the diagnostic performance of a six-protein diagnostic panel.
05 Dec 2024
- Application focus
Using NGS-Based Proteomics to Differentiate BTK Inhibitor Response in Leukemia
This webinar will highlight a study that compares the effect of three different BTK inhibitors: ibrutinib, acalabrutinib, and zanubrutinib. Patient samples were obtained before and at various time points after treatment to identify biomarkers that could be informative of the treatment’s effects.
18 Feb 2025